Prosecution Insights
Last updated: October 02, 2026
Application No. 17/064,483

OSTEOCHONDRAL/SUBCHONDRAL TREATMENT SYSTEM

Final Rejection §112
Filed
Oct 06, 2020
Priority
Oct 31, 2019 — provisional 62/928,907 +1 more
Examiner
HU, ANN M
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
In2Bones Usa LLC
OA Round
7 (Final)
68%
Grant Probability
Favorable
8-9
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
645 granted / 952 resolved
-2.2% vs TC avg
Strong +22% interview lift
Without
With
+21.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
43 currently pending
Career history
1007
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
48.1%
+8.1% vs TC avg
§102
27.0%
-13.0% vs TC avg
§112
17.7%
-22.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 952 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments The 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejection, cited in the office action of 6/23/2026, has been maintained, as the claim has not been amended to address the broad limitation together with a narrow limitation issue. Applicant’s remaining arguments with respect to claim(s) 1-3 and 6-19 have been considered, but are moot in view of the new grounds of rejection. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1 and its dependent claims are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 1 recites the broad recitation “a positive or negative curvature height to ensure compatibility with surrounding cartilage tissue,” and the claim also recites “the height of the implant is…elevating the top portion above the surrounding cartilage tissue,” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Appropriate correction is required. The amendments made to claim 1 recite a first transition surface that smoothly joins the bottom portion with a cylindrical sidewall extending vertically to a second transition surface that smoothly joins the cylindrical sidewall. It is unclear how the first transition surface of the amendment is intended to be a different element from the rounded periphery comprising a first transition surface recited in claim 1, lines 5-8. Likewise, it is unclear how the second transition surface of the amendment differs from the second transition surface recited in claim 1, lines 14-15. As presently worded, the metes and bounds of the claim language cannot be accurately determined. Appropriate correction is required. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Hu whose telephone number is (571) 272-6652. The examiner can normally be reached on Monday-Friday (9:00 am-5:30 pm EST). If attempts to reach the examiner by telephone are unsuccessful, please contact the examiner’s supervisor, Jerrah Edwards, at (408) 918-7557. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANN HU/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Show 15 earlier events
May 22, 2025
Response after Non-Final Action
Sep 24, 2025
Final Rejection mailed — §112
Nov 20, 2025
Response after Non-Final Action
Dec 03, 2025
Request for Continued Examination
Dec 16, 2025
Response after Non-Final Action
Mar 23, 2026
Non-Final Rejection mailed — §112
Jun 23, 2026
Response Filed
Sep 16, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746120
CONTROLLABLY DEPLOYABLE PROSTHETIC VALVE
3y 7m to grant Granted Sep 29, 2026
Patent 12746307
CARTILAGE TREATMENT FOR USE IN EYELID RECONSTRUCTION
2y 11m to grant Granted Sep 29, 2026
Patent 12740868
MEDIALLY STABILISING KNEE ENDOPROSTHESIS
2y 8m to grant Granted Sep 22, 2026
Patent 12727993
EXPANDABLE SEALING SKIRT TECHNOLOGY FOR LEAK-PROOF ENDOVASCULAR PROSTHESES
6y 4m to grant Granted Sep 08, 2026
Patent 12727990
Temporary Keratoprosthesis, Corneal Transplant Suturing Jig, Temporary Endoprosthesis, and Method of Using
3y 4m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

8-9
Expected OA Rounds
68%
Grant Probability
89%
With Interview (+21.6%)
3y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 952 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month